乳腺癌分子分型与新辅助化疗疗效相关性地研究.docxVIP

Abstract Obj ective Neoadjuvant chemotherapy(NCT)is becoming the standard of care for patients 、析m locally advanced breast cancer(LABC)and is increasingly being used in the treatment ofpatients、析nl early breast c；ancgr．The main aim ofNCT is to downstage the till／lOt load to increase the rate of breast-conserving surgery and to gain information on drug response by in-breast assessment．We all know that breast cancer is a heterogeneous disease，therefore，tunlor谢m the same clinicalpathological characteristics may be diverse in disease behavior,response to therapy and prognostic． The prediction of the possibility of pCR before starting NCT can be used to maximize the treatment effect and minimize unnecessary toxicity．Nevertheless，there is little known about the relevance between molecular subtypes and NCT sensitivities in the Chinese population．Our study is aimed to evaluate the role of molecular subtypes in predicting the response to NCT among breast cancer patients in Northeast China． Methods One hundred and two patients who were initially diagnosed by COre needle biopsy and treated with NCT followed by definitive surgical resection were retrieved from the First Affiliated Hospital，China Medical University,Shenyang，China．NCT regimens contained cyclophosphamide，epirubicin and flurouracil(CEF)；docetaxel plus earboplatin(TCb)；and docetaxel plus epirubincin(TE)．Prior to NCT,1 4-gauge biopsies of the breast tumor were taken under ultrasound guidance to determine the 3 were used to divided 1 02 breast cancelS treate《1 with neoadjuvant chemotherapy(NCT) into 4 subtypes：htminal A(ER+，PR+，脏R2一，and ki-67 S14％)，luminal B正R+， PR+，脏R2一，and ki-6714％；ER+and／or PR+，HER2+)，HER2-overexpression 正R一，PR一，and HER2+)and triple·negative(ER一，PR一，and HER2--)． Results Among 1 02 patients，a pCR was seen in 1 6(15．7％)patients．111e pCR rates according to different subtypes are as follows：luminal A 0 of 20(o．O％)，luminal B 2 of 23(8．7呦，HER2-overexpression 4 of 18(22．2％)，and triple-negative 1 0 of